Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Date:3/31/2011

NEW YORK, March 31, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind  Phase II clinical trial of obeticholic acid (OCA) given as monotherapy to patients with primary biliary cirrhosis (PBC).  The study evaluated the effects of 10 mg and 50 mg of OCA compared with placebo in patients with elevated alkaline phosphatase (AP).  AP is a liver enzyme routinely used to evaluate the clinical status and disease progression of PBC patients.

At the end of the 12 week treatment period, both doses of OCA produced statistically highly significant reductions in AP, the primary endpoint, compared with the patients receiving placebo (changes: 10mg:  -45%; 50mg:  -38%; placebo:  0%; p < 0.0001 both doses versus placebo). There were also significant improvements in other liver enzymes, including gamma-glutamyl transferase. In addition, serum markers of inflammation and immunity also improved with significant reductions of C-reactive protein (CRP), and immunoglobulin M (IgM), which is closely associated with the autoimmune dysfunction in PBC.  Pruritus (itch) was seen more commonly in the OCA treated patients and increased with dose; otherwise, all other adverse events were generally similar across the groups.

PBC is a chronic autoimmune disease of the liver marked by the slow progressive destruction of the small bile ducts within the liver which may lead to liver failure and the need for liver transplantation. PBC primarily afflicts women with up to 300,000 patients estimated in developed countries.  There is only one drug approved to treat the disease, ursodeoxycholic acid (UDCA), and up to 50% of PBC patients on UDCA therapy continue to be at significant risk of progression to cirrhosis.

Kris V. Kowdley, MD, Director of the Center for Liver Disease at Virginia Mason Medical Center, in Seattle, Washington and a principal investigator in the study, commented, "There is a real need for novel therapies in PBC.  The clinically meaningful results from this study are highly supportive of OCA's potential as an effective new drug. We know now that OCA is effective given both in addition to UDCA and, from this study, when given alone.  The reductions in AP levels were very substantial and occurred within a month.  The effects on IgM and inflammatory markers suggest that OCA may have disease modifying properties."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved 20 centers in 7 countries and has given us and the PBC thought leaders involved a better understanding of the potent mechanism of action of OCA.  With the international PBC network we have established, we are well positioned to conduct a Phase III program.  We are currently discussing requirements for approval with FDA and have received guidance from the EMA supportive of our proposed program."

Mark Pruzanski, MD, Intercept's Chief Executive Officer, added, "The remarkable results achieved with OCA treatment in this study, together with the previously announced positive Phase II results with our drug added to UDCA in refractory PBC patients and in diabetic patients with nonalcoholic fatty liver disease, supports OCA's potential as a novel hepatoprotective drug that may help preserve liver function in patients with a variety of chronic liver diseases."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist. Intercept has announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, and in type 2 diabetics with nonalcoholic fatty liver disease.  These clinical data and OCA's mechanism of action support its potential as a novel hepatoprotective agent in a broad range of chronic liver diseases. Intercept is currently preparing for the initiation of a Phase III PBC program in the U.S. and Europe and OCA is also being evaluated in a large NIDDK-run placebo-controlled nonalcoholic steatohepatitis (NASH) trial that recently started enrolling in the US.

About Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic liver and metabolic diseases.  The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidneys, organs that are exposed to bile acid flux.

For more information about Intercept, please go to www.interceptpharma.com.

For information about Intercept's majority shareholder Genextra S.p.A., please go to www.genextra.it.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
6. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
7. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
8. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
11. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... TomoTherapy® Systems continue to set the bar for excellence ... composite overall user satisfaction rating among radiation treatment delivery ... MD Buyline Market Intelligence Briefing™. The most recent ratings ... ratings among industry peers for 11 of the past ...
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. (Nasdaq: ... federal institution supporting research in Germany ... patient treatments at the University Clinic Heidelberg as part ... The MRIdian Linac program will be headed by Medical ... heads radiation oncology at the German Cancer Research Center ...
(Date:1/19/2017)... -- New Review of Safinamide - ... and Motor Complications in Mid- to Late-stage Parkinson,s ... ... C Warren Olanow , ... 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published recently ...
Breaking Medicine Technology:
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ... 2017 , ... The VA Maryland Health Care System and ... project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, PhD, an ... disease without compromising normal immune function that often occurs during autoimmune diseases. Ultimately ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... most-read publication among specialty pharmacists and pharmacy professionals, has teamed up with ... Partnership (SAP) program, announced Brian Haug, president of Pharmacy Healthcare Communications, LLC, ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor plans to run the ... charity that provides free surgery to poor children suffering from cleft lip and cleft ... have run to support the efforts of the American Heart Association and the Leukemia ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a ... business owners in central Maryland and the DC region, is inaugurating a charity event ... people nationally every year, making it the #1 killer in America. However, heart disease ...
Breaking Medicine News(10 mins):